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Cytomegalovirus (CMV) establishes a persistent latent infection in the human
host. Healthy individuals rarely suffer from disease symptoms during primary
infection nor do they experience symptomatic reactivation of the resident virus. In
indivicJuals with a deficient immune systern primary infection or reactivation of the
virus may lead to serious illness. In most individuals the (deficient) immune
system manages to clear the host from an active CMV infection. So far a non-
complicated therapy against CMV is not available.
Predominantly CMV is a cell-bound virus. Therefore the cell membrane is
likely to contain the prime targets for elimination of the virus by the immune
system. The aim in the present study was to characterize the specific membrane
antigens which are recognized by the humoral immune system. An additional goal
was to monitor humoral responses against these antigens.
In chapter 1 an introduction into CMV, CMV antigens, treatment and prophy-
laxis of CMV infection in renal transplant patients and immune responses against
CMV is given. Special emphasis is given to the recent advances in the field of
viral glycoproteins and the role of membrane antigens in specif,rc defense mecha-
nisms.
The isolation and characterization of monoclonal antibodies against viral
membrane antigens is described in chapter 2. Partially purified plasma membrane
vesicles prepared from infected fibroblasts were used to immunize mice. The
selection of hybridomas was based on membrane fluorescence techniques. These
experiments resulted in the isolation of only one type of monoclonal antibodies.
The three polypeptides precipitated by this type of monoclonal antibodies were
identified as members of the gcl family of glycoproteins.
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The fact that only a limited number of viral antigens is recognized by human
antibodies was revealed by studies described in chapter 3. Next to two gcl
polypeptides with molecular masses of 53-63 and 94-120 kDa, only one other
polypeptide was precipitated from cell extracts prepared from CMV-infected
surface-labelled fibroblasts by human antibodies. This 94 kD polypeptide was
identified as a member of the gcIII family of glycoproteins. It was also shown that
the number of surface polypeptides recognized before and after onset of active
secondary CMV infection in renal transplant recipients remained the same.
Quantitation of the humoral responses against specific CMV antigens using
immunoprecipiation methods or immunoblotting methods has proven to be
difficult. Therefore two methods were developed to study immunological responses
against single antigens in more detail. The method described in chapter 4 is based
on the use of cloned fragments of the CMV genome. These fragments were ex-
pressed as fusion proteins in Escherichia coli. The fusion proteins proved to be
useful as antigens in an enzyme-linked immunosorbent assay (ELISA). A drawback
of this type of antigens is that the fusion proteins contain only a fragment of the
CMV antigen and that this antigenic fragment is denatured during isolation of the
fusion protein. The second method to detect antibody responses against single
antigens was based on the capture of specific antigens by monoclonal antibodies.
The specific antigen was bound to a monoclonal antibody that was immobilized in
a microtiterplate, subsequently an ELISA was performed. The captured antigen is
in its native state and thus contains linear as well as conformational antigenic epi-
topes. Chapter 5 contains a detailed description of the development of this assay.
The antigen capture immunoassay was used to study the responses against two
different CMV antigens in healthy individuals, in patients with chronic renal
failure and in renal transplant recipients suffering from primary or secondary
CMV infections. These antigens were a gcl polypeptide described in chapters 2
and 3, and the major immediate early antigen of CMV. The latter antigen is an
intracellular antigen, but appears to be important in T-cell mediated cytotoxicity.
In chapter 6 highly individual patterns of humoral responses against these two
CMV antigens were demonstrated, moreover distinct differences in the kinetics of
development of the two types of antibodies were demonstrated. In most patients
suffering from a primary or a secondary CMV infection first detection of, or a
significant rise of antibodies against the immediate early antigen preceded the first
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